Insurance-Driven Switching and Real-World Treatment Outcomes of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study - PubMed
4 days ago
- #Alopecia Areata
- #Real-World Outcomes
- #JAK Inhibitors
- Study focuses on insurance-driven switching of Janus Kinase (JAK) inhibitors in alopecia areata treatment.
- Retrospective cohort study evaluates real-world treatment outcomes of JAK inhibitors.
- Key JAK inhibitors mentioned include Baricitinib, Ritlecitinib, and Tofacitinib.
- Outcomes measured include efficacy, hair regrowth, and changes in SALT score.
- Study also examines treatment duration and the impact of insurance authorization on treatment switching.